用精准医学方法在BEST-CLI试验中识别慢性肢体威胁性缺血的疾病分期
基于BEST-CLI国际随机对照试验数据,采用监督潜在主题模型识别与截肢-free生存相关的患者特征聚类,分出三个疾病分期;不同分期在开放旁路和血管内治疗下的2年死亡率和截肢-free生存率存在差异,分期特征包括伤口、糖尿病、肾病及WIfI分级等。
要点
- 精准医学方法在BEST-CLI数据中识别出三个CLTI疾病分期。
- 分期1患者较少有伤口、糖尿病和肾病,分期3合并症负担最重。
- 不同分期在开放旁路和血管内治疗下的2年结局存在差异。
核心结论
- 使用精准医学方法在BEST-CLI随机临床试验数据中识别出三个不同的CLTI疾病分期。
研究设计与样本
- 基于BEST-CLI国际随机对照试验数据,按分配的血管重建类型分层后,采用监督潜在主题模型识别与截肢-free生存相关的患者特征聚类。
- 患者被分配到概率最高的聚类,并通过分析聚类内患者特征来刻画各聚类。
主要发现
- 开放旁路组三个分期的2年死亡率分别为11.59%、20.91%和24.73%,2年截肢-free生存率分别为83.26%、70.03%和65.82%。
- 血管内治疗组分期1、2、3的2年死亡率分别为15.88%、22.62%和20.32%,2年截肢-free生存率分别为77.98%、66.06%和67.74%。
- 分期1一般包括较少有伤口、糖尿病和肾病的患者;分期2主要由糖尿病和部分足部感染驱动;分期3以高合并症率(尤其是终末期肾病和糖尿病)及更高的WIfI分级为特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease, is associated with a high risk of limb loss. CLTI clinical presentation is highly heterogeneous, ranging from neuropathic ulcers with only mild to moderate ischemia to gangrene resulting from severe ischemia. Understanding the etiology and limb- and systemic-based disease patterns, as well as differential procedural risks and outcomes, is pivotal for making treatment choices over the course of this chronic disease. In other words, accurate staging (and restaging over time) of CLTI that includes limb-based and systemic features is needed to improve the treatment decision-making process and clinical outcomes. Precision medicine analytics can integrate and synthesize multimodal data, in this case anatomy data alongside comorbidities and physical examination findings, offering a more complete staging system from which to make nuanced treatment decisions well-tailored to patient-specific risks. METHODS: Using data from the BEST-CLI (Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia) international randomized controlled trial, we used supervised latent topic modeling to identify clusters of patient features associated with amputation-free survival after stratifying for each assigned revascularization type. Patients were assigned to the cluster they belonged to with highest probability; clusters were characterized by analyzing the characteristics of patients within them. Although the clusters were not naturally ordinal, we subsequently organized them to mirror stages of disease progression for clearer clinical interpretation. RESULTS: Based on patient- and limb-focused characteristics, we identified three distinct clusters as disease stages. Across the three stages, rates of 2-year mortality were 11.59%, 20.91%, and 24.73% and rates of 2-year amputation-free survival were 83.26%, 70.03%, and 65.82%, respectively, for patients undergoing open bypass. Patients receiving endovascular therapy had 2-year mortality rates of 15.88%, 22.62%, and 20.32% and 2-year amputation-free survival rates of 77.98%, 66.06%, and 67.74%, respectively, for stages 1, 2, and 3. Stage 1 generally included patients who were less likely to have wounds, diabetes, and renal disease. Stage 2 was primarily driven by diabetes and some foot infection. Stage 3 is characterized by high rates of comorbidities, particularly end-stage renal disease and diabetes, as well as higher Wound, Ischemia, and foot Infection grades. CONCLUSIONS: We identified three distinct stages of CLTI using precision medicine methods. The results from this analysis of the BEST-CLI randomized clinical trial dataset are consistent with previous findings in other cohorts. Future research focused on tailored treatment algorithms for each specific stage of CLTI is warranted.
引用
- Zhou CW, Hoch M, Freeman NLB, et al. Using precision medicine methods to identify disease stages for chronic limb-threatening ischemia in participants of the BEST-CLI trial. J Vasc Surg. 2025. PMID: 41167383. doi:10.1016/j.jvs.2025.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。